Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Research analysts at Jefferies Financial Group lowered their FY2022 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft now expects that the company will earn ($1.96) per share for the year, down from their prior forecast of ($1.94). The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($1.94) per share. Jefferies Financial Group also issued estimates for Karyopharm Therapeutics' Q4 2022 earnings at ($0.38) EPS, Q2 2023 earnings at ($0.24) EPS, Q3 2023 earnings at ($0.26) EPS, Q4 2023 earnings at ($0.25) EPS, FY2023 earnings at ($1.05) EPS, FY2024 earnings at ($0.82) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at $0.49 EPS and FY2027 earnings at $0.89 EPS.
Get
Karyopharm Therapeutics alerts:
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.11. The business had revenue of $36.15 million during the quarter, compared to the consensus estimate of $34.82 million.
A number of other equities analysts have also commented on the company. SVB Leerink dropped their price target on Karyopharm Therapeutics from $6.00 to $5.00 and set a "market perform" rating for the company in a research note on Tuesday, January 10th. Morgan Stanley dropped their price target on Karyopharm Therapeutics from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Friday, January 27th. Piper Sandler started coverage on Karyopharm Therapeutics in a research note on Thursday, January 19th. They set an "overweight" rating and a $8.00 price target for the company. Royal Bank of Canada raised Karyopharm Therapeutics from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $7.00 to $10.00 in a research note on Friday, November 4th. Finally, StockNews.com lowered Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, November 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, Karyopharm Therapeutics currently has an average rating of "Hold" and an average price target of $9.33.
Karyopharm Therapeutics Stock Down 3.1 %
NASDAQ KPTI opened at $3.40 on Monday. The firm has a market cap of $275.91 million, a price-to-earnings ratio of -2.98 and a beta of -0.04. The business has a 50-day moving average price of $3.53 and a 200-day moving average price of $4.50. Karyopharm Therapeutics has a twelve month low of $2.45 and a twelve month high of $14.73.
Institutional Investors Weigh In On Karyopharm Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Metropolitan Life Insurance Co NY raised its holdings in shares of Karyopharm Therapeutics by 73.9% in the third quarter. Metropolitan Life Insurance Co NY now owns 4,622 shares of the company's stock worth $25,000 after buying an additional 1,964 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Karyopharm Therapeutics by 612.5% in the third quarter. Nisa Investment Advisors LLC now owns 5,700 shares of the company's stock worth $26,000 after buying an additional 4,900 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $34,000. Prelude Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $53,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $54,000. 96.13% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
(Get Rating)
Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Recommended Stories
- Get a free copy of the StockNews.com research report on Karyopharm Therapeutics (KPTI)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
